Venture Building/Incubation/Capital Formation
Ezra Bridge builds the investment case, defends the valuation, structures the round, and leads the raise. Selectively, and on our own name.
An investor forms a view in the first few minutes, and forms it on documents. Being understood, priced credibly, and structured cleanly is produced work. Most companies have never had anyone produce it properly, so the business is judged on the worst artefact anyone ever made about it.
A deck is not a case. An introduction is not a round. Both are billed on delivery, and neither party carries any consequence if the company never closes. Nobody has ever been fired for producing a beautiful deck for a business that failed to raise.
We build the case, defend the number, structure the round, and run the process through to close. Before any of it, one test: whether we would put our own name behind this company, in front of investors we intend to work with again.
Everything else follows from that. The case, the valuation, the structure, the documents, and the story each have to stand on their own before an investor sees any of it. When they do not, the answer is more work, or no mandate. It is not a better-looking deck.
We diagnose what is missing between what you have and what an investor needs, build it, price the company defensibly, structure the round, and run the raise.
What a mandate involves→Every company that reaches you has already been diagnosed, priced against comparables, and structured. You see the file, not the pitch.
How access works→Ezra Bridge does not advise from the sidelines. BuildIQ and Revaia were built inside the practice and taken through the same seven stages we run for every mandate. 21M Labs is not ours: it is an independent lab we fund and venture-build alongside, and it is where BuildIQ came from. The standard we hold a client to is the one we applied to ourselves first.
A drawing set goes in. A priced bill of quantities comes out. The three weeks in between are the product.
Pricing a building still means a senior estimator tracing lines over a drawing set with a highlighter for two to four weeks, then doing it again every time the architect issues a revision. BuildIQ rebuilds the geometry the export threw away, classifies it, measures it, and prices it against live supplier rates. The estimate is then held as the live budget for the rest of the job.
Opened inside 21M Labs as file 001, and venture-built by Ezra Bridge once it held. Positioned as AI-assisted take-off validated by the contractor, not full automation, and not claimed as such.
BuildIQ in full→A net-60 invoice is a sixty-day loan at zero percent, written by a supplier to a buyer many times its size.
Revaia advances against invoices a business has already earned, settles in stablecoin within a day, and then tracks repayment from the debtor so the supplier never has to chase its own customer. The capital behind the advance comes from an institutional pool rather than a balance sheet, and the yield those advances generate accrues to the participants in it.
Invoice financing is the product on day one. The direction is broader: working capital and banking infrastructure for the businesses the incumbent system prices worst.
Revaia in full→An independent lab in Denver that opens more files than it finishes, and writes down in advance what would make it stop.
21M Labs is not an Ezra Bridge company. It is an independent technology lab we fund and venture-build alongside, and it is the closest thing this practice has to proprietary origination. The lab runs many small bets under one procedure. When a file proves that people come back to it, Ezra Bridge takes it through the same seven stages as any external mandate and builds it into a company. BuildIQ is the first one that made it.
The lab keeps autonomy over what it opens and which verticals it works in. We do not get a vote on that. The arrangement covers funding and venture building, and it stops there, which is what keeps the origination honest.
21M Labs in full→Alongside the ventures built in-house, Ezra Bridge takes selected external mandates through the same seven stages. Client identities are held confidential and disclosed under NDA.
| Company | Sector | Engagement | Year |
|---|---|---|---|
| Name withheld, disclosed under NDA | Medical diagnostics | Investor readiness | 2026 |
| Name withheld, disclosed under NDA | Consumer health | Investor readiness | 2026 |
The redactions are the point. A firm that would name you in its marketing before your round closes is a firm that will name the next company too.
The complete set an institutional investor expects, built in sequence, every document carrying the same numbers because they are generated from the same defended case.
The deck and the teaser are built last, not first. They compress a deal that has already been priced and structured, which is why their numbers can be trusted.
Why the deck comes last→Most of this industry treats its method as the product and keeps it private. We would rather be judged on it.
How a number should be arrived at, what makes a comparable worth citing, and why the honest outcome is sometimes that there is no supportable number yet.
Why top-down sizing fails, how to decompose an opportunity across the verticals a product can credibly reach, and why the honest number is usually smaller and worth more.
Almost everyone starts with the deck. It is the wrong end of the process, and it is why so many decks contain numbers the company cannot stand behind.
Every mandate is run by a principal. There is no layer of analysts between the diagnosis and the person who signs their name to it, which is the only way the standard on this page survives contact with a deadline. Two people, both of whom have built the thing they are now pricing.
Both operate across several domains at once. It is the reason the ventures on this page exist rather than being described, and the reason a diagnosis here comes from people who have had to ship the answer themselves.